Kolexia
Olympios-Gerotzortzos Nathalie Oncologie médicale
Olympios-Gerotzortzos Nathalie
Oncologie médicale
Centre Henri-Becquerel
Rouen, France
38 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Tumeurs du poumon Tumeurs des glandes endocrines Tumeurs de l'ovaire Carcinome pulmonaire non à petites cellules Tumeurs de la tête et du cou Carcinome pulmonaire à petites cellules Glioblastome {{person.topmesh10.name}}

Collaborateurs

Voir plus
Allouchery Violette
Allouchery Violette
Centre Henri-Becquerel, Rouen, France
Lacaud Marine
Lacaud Marine
Hôpital Jacques Monod, Montivilliers, France
Clatot Florian
Clatot Florian
Centre Henri-Becquerel, Rouen, France
Jamelot Mathieu
Jamelot Mathieu
Hôpital Tenon, Paris, France

Industries

Voir plus
A+A
8 collaboration(s)
Dernière en 2023
AstraZeneca
3 collaboration(s)
Dernière en 2023
Lilly
2 collaboration(s)
Dernière en 2023
Merck-Serono
1 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
IMMUNOVASC: Evaluation of Vascular Toxicity of Immune Checkpoint Inhibitors (Nivolumab, Pembrolizumab, Atezolizumab) in Patients Head and Neck or Lung Cancer
Essai Clinique (Centre Henri-Becquerel)   09 décembre 2022
Diagnostic and predictive accuracy of anti-mullerian hormone for ovarian function after chemotherapy in premenopausal women with early breast cancer.
Breast cancer research and treatment   08 janvier 2022
Analyses of the Rationale and Implementation of Research Biopsies in Oncology Clinical Trials at a Tertiary Cancer Center.
The oncologist   04 août 2021
Use of a high-sensitivity anti-Mullerian hormone (AMH) assay to determine ovarian function after chemotherapy for early breast cancer.
2021 ASCO Annual Meeting I   28 mai 2021
Promoter Alterations in Glioblastoma: A Systematic Review.
Cancers   08 mars 2021
Impact of financial considerations on French physicians’ prescription choices for advanced non-small cell lung cancer (NSCLC)
Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September – 1 October 2019, Barcelona, Spain   01 octobre 2019
Impact of Taxanes, Endocrine Therapy, and Deleterious Germline Mutations on Anti-müllerian Hormone Levels in Early Breast Cancer Patients Treated With Anthracycline- and Cyclophosphamide-Based Chemotherapy.
Frontiers in oncology   12 juillet 2019
Impact of deleterious germline BRCA mutations, addition of taxanes and use of adjuvant endocrine therapy (ET) on anti-müllerian hormone (AMH) levels in early breast cancer (EBC) patients treated by adjuvant chemotherapy (CT)
Abstract Book of the 43rd ESMO Congress (ESMO 2018) 19–23 October 2018, Munich, Germany   01 octobre 2018
{{person.lastact9.name}}
{{person.lastact9.jour}}   {{person.lastact9.date}}
{{person.lastact10.name}}
{{person.lastact10.jour}}   {{person.lastact10.date}}